company background image
688221 logo

Frontier Biotechnologies SHSE:688221 Stock Report

Last Price

CN¥9.68

Market Cap

CN¥3.7b

7D

7.1%

1Y

3.6%

Updated

25 Dec, 2024

Data

Company Financials

Frontier Biotechnologies Inc.

SHSE:688221 Stock Report

Market Cap: CN¥3.7b

688221 Stock Overview

A commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. More details

688221 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Frontier Biotechnologies Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Frontier Biotechnologies
Historical stock prices
Current Share PriceCN¥9.68
52 Week HighCN¥10.71
52 Week LowCN¥4.48
Beta0.76
1 Month Change26.04%
3 Month Change92.83%
1 Year Change3.64%
3 Year Change-44.78%
5 Year Changen/a
Change since IPO-67.64%

Recent News & Updates

Recent updates

Shareholder Returns

688221CN BiotechsCN Market
7D7.1%-0.7%0.4%
1Y3.6%-18.4%12.3%

Return vs Industry: 688221 exceeded the CN Biotechs industry which returned -18.4% over the past year.

Return vs Market: 688221 underperformed the CN Market which returned 12.3% over the past year.

Price Volatility

Is 688221's price volatile compared to industry and market?
688221 volatility
688221 Average Weekly Movement11.5%
Biotechs Industry Average Movement8.9%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 688221's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688221's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2013395C. J. Wangwww.frontierbiotech.com

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS.

Frontier Biotechnologies Inc. Fundamentals Summary

How do Frontier Biotechnologies's earnings and revenue compare to its market cap?
688221 fundamental statistics
Market capCN¥3.74b
Earnings (TTM)-CN¥279.96m
Revenue (TTM)CN¥133.67m

27.1x

P/S Ratio

-13.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688221 income statement (TTM)
RevenueCN¥133.67m
Cost of RevenueCN¥84.16m
Gross ProfitCN¥49.51m
Other ExpensesCN¥329.47m
Earnings-CN¥279.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin37.04%
Net Profit Margin-209.43%
Debt/Equity Ratio39.0%

How did 688221 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:08
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Frontier Biotechnologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution